Selection of solid dosage form composition through drug-excipient compatibility testing.
A drug-excipient compatibility screening model was developed by which potential stability problems due to interactions of drug substances with excipients in solid dosage forms can be predicted. The model involved storing drug-excipient blends with 20% added water in closed glass vials at 50 degrees C and analyzing them after 1 and 3 weeks for chemical and physical stability. The total weight of drug-excipient blend in a vial was usually kept at about 200 mg. The amount of drug substance in a blend was determined on the basis of the expected drug-to-excipient ratio in the final formulation. Potential roles of several key factors, such as the chemical nature of the excipient, drug-to-excipient ratio, moisture, microenvironmental pH of the drug-excipient mixture, temperature, and light, on dosage form stability could be identified by using the model. Certain physical changes, such as polymorphic conversion or change from crystalline to amorphous form, that could occur in drug-excipient mixtures were also studied. Selection of dosage form composition by using this model at the outset of a drug development program would lead to reduction of "surprise" problems during long-term stability testing of drug products.
Pharmaceutics R&D Department, Bristol-Myers Squibb Pharmaceutical Research Institute, New Brunswick, New Jersey 08903, USA.
A T
AT
Serajuddin
A B
AB
Thakur
R N
RN
Ghoshal
M G
MG
Fakes
S A
SA
Ranadive
K R
KR
Morris
S A
SA
Varia
D002121:Calcium Channel Blockers / Q000737:chemistry; D002851:Chromatography, High Pressure Liquid; D003460:Crystallization; D004304:Dosage Forms; D004355:Drug Stability; D005079:Excipients / Q000494:pharmacology*; D017328:Fosinopril / Q000737:chemistry; D012995:Solubility
D002121:Calcium Channel Blockers; D004304:Dosage Forms; D005079:Excipients; D017328:Fosinopril